Completed PHASE4 INTERVENTIONAL 2-arm NCT00618449

Impact of Two Alternative Dosing Strategies for Trachoma Control in Niger

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Conditions Chlamydia Trachomatis Trachoma

Updated 6 times since 2017 Last updated: Apr 10, 2012 Started: Jan 31, 2008 Primary completion: May 31, 2009 Completion: Aug 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00618449, this PHASE4 trial focuses on Chlamydia Trachomatis and Trachoma and remains completed. Sponsored by National Institute of Allergy and Infectious Diseases (NIAID), it has been updated 6 times since 2008, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Dec 2021 — Jul 2024 [monthly]

Completed PHASE4
Jan 2021 — Dec 2021 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Jan 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Institute of Allergy and Infectious Diseases (NIAID)
University of California, San Francisco

Data source: University of California, San Francisco

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Niamey, Niger
• San Francisco, United States